Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma

Annals of the New York Academy of Sciences

Volumn 941, Issue , 2001, Pages 155-165

  Heald, Peter ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Skin scoring methods; Therapy of cutaneous T cell lymphoma

Indexed keywords

CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; OUTCOMES RESEARCH; QUESTIONNAIRE; SCORING SYSTEM; T CELL LYMPHOMA;

EID: 0034808661     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03719.x     Document Type: Conference Paper

References (10)

1. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group
2. CD8 positive tumor infiltrating lymphocytes influence the long term survival of patients with mycosis fungoides
3. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis based treatment
4. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups
5. Treatment of cutaneous T cell lymphoma by extracorporeal photochemotherapy: Preliminary results
6. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides
7. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T-cell lymphoma: Multinational phase II-III trial results
8. Topical bexarotene therapy for patients with refractory or persistent early stage cutaneous T-cell lymphoma: Results of a phase III clinical trial
9. Utility of PCR amplification of T-cell receptor rearrangements in the definition of cutaneous T-cell lymphoma relapse
10. Cutaneous T-cell lymphoma